Neumora's depression drug fails Phase 3, Pfizer exits Sangamo hemophilia A gene therapy partnership, and biotech sees surge in megarounds with 96 nine-figure financings in 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback